Nasal spray drug related to ketamine approved by FDA to treat depression
Companies, agencies, institutions, etc
The U.S. Food and Drug Administration
The Johnson & Johnson
FDA
the Division of Psychiatry Products
Center for Drug Evaluation and Research
Yale University
the Yale Depression Research Program
NBC News
the World Health Organization
the Centers for Disease Control and Prevention
the Johnson & Johnson
Eli Lilly's
Shamard
NBC UNIVERSAL
People
Special K
Tiffany Farchione
Gerard Sanacora
Esketamine
Symbyax
Dr
Groups
American
Physical locations
No matching tags
Places
No matching tags
Locations
U.S.
the United States
said.“Most
Prozac
Events
No matching tags
Summary
It is especially effective in patients who have not benefited from at least two different therapies, also known as treatment-resistant depression, the FDA said.“There has been a long-standing need for additional effective treatments for treatment-resistant depression, a serious and life-threatening condition,” Dr. Tiffany Farchione, acting director of the Division of Psychiatry Products in the FDA's Center for Drug Evaluation and Research, said in a statement Tuesday.Intravenous infusions of ketamine have been shown to help people with severe depression who experience suicidal thoughts, but the laborious process to administer the medication could be frustrating to patients. Experts believe that the FDA approval of a quick-acting, easy-to-use spray treatmentis a pivotal moment in the history of mental health therapy.“This offers an extremely important, new treatment for people suffering with treatment-resistant depression,” Dr. Gerard Sanacora, professor of psychiatry at Yale University and director of the Yale Depression Research Program, told NBC News.
As said here by Shamard Charles, M.D.